Clinical case of Long-COVID complicated by the development of pneumocystis pneumonia in patient with follicular lymphoma

The COVID-19 pandemic has led to global consequences, including Long-COVID. This term is used to refer to the symptoms of a new coronavirus infection that last more than 4 weeks, but less than 12 weeks from the onset of the disease. The most common symptoms are shortness of breath, cough, and general weakness. The risk group for the long-term course of COVID-19 includes patients with immunodeficiency. One of the reasons for the long-term persistence of symptoms is the persistence of the virus in the body. However, in 30–40% of cases, the results of the SARS-CoV-2 test turn out to be negative, which makes it difficult to make a diagnosis. In addition, patients with immunodeficiency against Long-COVID may develop opportunistic infections caused by reactivated opportunistic microflora against the background of lymphopenia. The presented clinical example demonstrates a case of Long-COVID infection complicated by the development of pneumocystis pneumonia in a patient with follicular lymphoma. Timely diagnosis and initiation of specific treatment made it possible to stabilize the patient’s condition and prevent the fulminant course of pneumocystis infection.

1. https://data.who.int/dashboards/covid19/cases?n=c

2. Healthcare in Russia. 2023: Stat.sat./Rosstat, Moscow, 2023, 181 p.

3. Gao Y.D., Ding M. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. https://doi.org/10.1111/all.14657.

4. Nalbandian A., Sehgal K. et al. Post-acute COVID-19 syndrome. Nature medicine. 2021 Apr;27(4):601-15. https://doi.org/10.1038/s41591-021-01283-z.

5. Management of patients with long-term COVID and post-covid complications (including antiviral/immunomodulatory therapy). Algorithms for diagnosis and treatment. Therapy. 2023; 9(4S): 34–50. https://doi.org/10.18565/therapy.2023.4suppl.34-50.

6. Methodological recommendations “Features of the course of Long-term COVID infection. Therapeutic and rehabilitation measures”. Therapy. 2022; 1 (Appendix): 1-147. https://doi.org/10.18565/therapy.2022.1suppl.1-147.

7. Zhou F., Yu T. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.

8. Carmo A., Pereira-Vaz J. et al. Clearance and persistence of SARS-CoV-2 RNA in COVID-19 patients. J Med Virol. 2020; 92(10): 2227–31. https://doi.org/10.1002/jmv.26103.

9. Liu Y., Yan L.-M. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020; 20(6): 656–57. https://doi.org/10.1016/S1473-3099(20)30232-2.

10. Fung M., Babik J.M. COVID-19 in immunocompromised hosts: What we know so far. Clin Infect Dis. 2021; 72(2): 340–50. https://doi.org/10.1093/cid/ciaa863.

11. Pinato D.J., Tabernero J. et al.; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021. 2212. https://doi.org/10.1016/S1470-2045(21)00573-8.

12. Averyanov A.V., Sotnikova A.G., Lesnyak V.N. Pneumocystis pneumonia mimicking COVID-19. Clinical practice. 2020;11(2):87–92. https://doi.org/10.17816/clinpract34995.

13. Choi Y.J., Seo Y.B. et al. A Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 28;12(23):7375. https://doi.org/10.3390/jcm12237375.